What the large sample bought
The meta-analysis combined 54,629 fibromyalgia cases with 2,509,126 controls across 11 cohorts, a total of 2,563,755 people. The multi-ancestry genome-wide scan found 26 risk loci. That scale makes weak, distributed associations visible where smaller studies could not, but each locus carries a small population-level difference in probability. A ‘risk locus’ is not a mutation that explains the condition in one person or a clinical test.[1]
The strongest association involved a coding variant in HTT, the causal gene for Huntington's disease; gene prioritisation also highlighted the HTT regulator GPR52 and neural candidates including DCC, DRD2/NCAM1, MDGA2 and CELF4. Heritability enrichment concentrated in brain tissues and neural cells. The same gene appearing in two conditions does not make the conditions the same: a shared genomic region can act through different cells, pathways and effect sizes.[1]
Correlation stops at the population scale
Fibromyalgia's genetic correlations with low-back pain, post-traumatic stress disorder and irritable bowel syndrome exceeded 0.7. Those numbers describe shared inherited liability; they do not say that one condition causes another or that symptoms are ‘only psychological’. It also matters that cohorts used diagnosis codes from hospital or primary-care records: scale does not automatically remove differences in clinical assessment or misclassification.[1]
Despite large sex differences in fibromyalgia prevalence, the study found nearly identical genetic architecture in males and females. That weakens a simple account in which prevalence follows genetic difference and leaves other layers—diagnostic access, hormones, environment and measurement—open. Its clinical value today lies in a stronger research map dividing chronic pain into testable targets within nervous-system biology. Drug choice does not follow from these data.[1]